



## BioXcel Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

June 5, 2018

BRANFORD, Conn., June 05, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the Jefferies 2018 Global Healthcare Conference being held June 5 – 8, 2018 in New York City.

Details of the Conference:

Event: Jefferies Global Healthcare Conference  
Date: June 7, 2018  
Time: 3:00 - 3:25 PM ET

A live webcast of the presentation will be accessible through the Investors section of the company's website at [www.bioxccltherapeutics.com](http://www.bioxccltherapeutics.com). Following the conference, the webcast will be archived on the BioXcel Therapeutics, Inc. website for 30 days. In addition to his presentation, Dr. Mehta will be hosting 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with BTI management should contact their Jefferies representative.

### About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

### Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to BXCL701's advancement and development, the presentation of data at ASCO and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BioXcel's current expectations and various assumptions. BioXcel believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. BioXcel may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation, market conditions and the factors described under "Risk Factors" in BioXcel's prospectus dated March 7, 2018 and BioXcel's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as BioXcel's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. BioXcel cannot guarantee future results, events, levels of activity, performance or achievements. BioXcel does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

### Contact Information:

The Ruth Group  
Lee Roth/ Janhavi Mohite  
646-536-7012/7026  
[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)/ [jmohite@theruthgroup.com](mailto:jmohite@theruthgroup.com)

Source: BioXcel Therapeutics, Inc.